Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Preferred Stock Liabilities (2016 - 2017)

VYNE Therapeutics (VYNE) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $50.3 million as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Preferred Stock Liabilities rose 12.28% year-over-year to $50.3 million, compared with a TTM value of $50.3 million through Dec 2017, up 12.28%, and an annual FY2017 reading of $50.3 million, up 12.28% over the prior year.
  • Preferred Stock Liabilities was $50.3 million for Q4 2017 at VYNE Therapeutics, up from $44.8 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $50.3 million in Q4 2017 and bottomed at $44.8 million in Q4 2016.